151 related articles for article (PubMed ID: 15114430)
1. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays.
Daley-Yates PT; Kunka RL; Yin Y; Andrews SM; Callejas S; Ng C
Eur J Clin Pharmacol; 2004 Jun; 60(4):265-8. PubMed ID: 15114430
[TBL] [Abstract][Full Text] [Related]
2. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
Daley-Yates PT; Deans A; Mehta R; Sousa AR
Pulm Pharmacol Ther; 2022 Dec; 77():102171. PubMed ID: 36243386
[TBL] [Abstract][Full Text] [Related]
3. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.
Fardon TC; Lee DK; Haggart K; McFarlane LC; Lipworth BJ
Am J Respir Crit Care Med; 2004 Nov; 170(9):960-6. PubMed ID: 15184207
[TBL] [Abstract][Full Text] [Related]
4. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.
Affrime MB; Kosoglou T; Thonoor CM; Flannery BE; Herron JM
Chest; 2000 Dec; 118(6):1538-46. PubMed ID: 11115437
[TBL] [Abstract][Full Text] [Related]
5. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate.
Crim C; Pierre LN; Daley-Yates PT
Clin Ther; 2001 Sep; 23(9):1339-54. PubMed ID: 11589253
[TBL] [Abstract][Full Text] [Related]
6. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD
Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.
Tayab ZR; Fardon TC; Lee DK; Haggart K; McFarlane LC; Lipworth BJ; Hochhaus G
Br J Clin Pharmacol; 2007 Nov; 64(5):698-705. PubMed ID: 17509041
[TBL] [Abstract][Full Text] [Related]
8. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group.
Mandl M; Nolop K; Lutsky BN
Ann Allergy Asthma Immunol; 1997 Sep; 79(3):237-45. PubMed ID: 9305231
[TBL] [Abstract][Full Text] [Related]
9. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
[TBL] [Abstract][Full Text] [Related]
10. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model.
Daley-Yates PT; Richards DH
Clin Ther; 2004 Nov; 26(11):1905-19. PubMed ID: 15639702
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
Derendorf H; Munzel U; Petzold U; Maus J; Mascher H; Hermann R; Bousquet J
Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350
[TBL] [Abstract][Full Text] [Related]
12. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations.
Daley-Yates PT; Baker RC
Br J Clin Pharmacol; 2001 Jan; 51(1):103-5. PubMed ID: 11167672
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
[TBL] [Abstract][Full Text] [Related]
14. Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis.
Mak KK; Ku MS; Lu KH; Sun HL; Lue KH
Pediatr Neonatol; 2013 Aug; 54(4):239-45. PubMed ID: 23597528
[TBL] [Abstract][Full Text] [Related]
15. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis.
Gradman J; Caldwell MF; Wolthers OD
Clin Ther; 2007 Aug; 29(8):1738-47. PubMed ID: 17919555
[TBL] [Abstract][Full Text] [Related]
16. The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers.
Mackie AE; Bye A
Clin Pharmacokinet; 2000; 39 Suppl 1():47-54. PubMed ID: 11140433
[TBL] [Abstract][Full Text] [Related]
17. Effect of intranasal fluticasone propionate and triamcinolone acetonide on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity in healthy volunteers.
Bachert C; Lukat KF; Lange B
Clin Exp Allergy; 2004 Jan; 34(1):85-90. PubMed ID: 14720267
[TBL] [Abstract][Full Text] [Related]
18. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis.
Skoner DP; Gentile D; Angelini B; Kane R; Birdsall D; Banerji D
Ann Allergy Asthma Immunol; 2003 Jan; 90(1):56-62. PubMed ID: 12546339
[TBL] [Abstract][Full Text] [Related]
19. Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol.
Hermann R; Locher M; Siebert-Weigel M; LaVallee N; Derendorf H; Hochhaus G
J Clin Pharmacol; 2004 May; 44(5):510-9. PubMed ID: 15102872
[TBL] [Abstract][Full Text] [Related]
20. Relative lung delivery of fluticasone propionate via large volume spacer or nebuliser in healthy volunteers.
Dempsey OJ; Humphreys M; Coutie WJ; Lipworth BJ
Eur J Clin Pharmacol; 2001 Nov; 57(9):637-41. PubMed ID: 11791892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
